

# Thiolated Amphiphilic $\beta$ -Cyclodextrin-decorated Gold Colloids: Synthesis, Supramolecular Nanoassemblies and Controlled Release of Dopamine

Mariachiara Trapani,<sup>a,†</sup> Angela Scala,<sup>b†</sup> Placido G. Mineo,<sup>c,d</sup> Alessandro Pistone,<sup>e</sup> Alejandro Díaz-Moscoso,<sup>f</sup> Alex Fragoso,<sup>f</sup> Luigi Monsù Scolaro,<sup>a,b,g</sup> and Antonino Mazzaglia<sup>\*a</sup>

<sup>a</sup> CNR-ISMN, Istituto per lo Studio dei Materiali Nanostrutturati c/o Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina, Viale F. Stagno d'Alcontres 31, Messina 98166, Italy

<sup>b</sup> Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina, Viale F. Stagno d'Alcontres 31, Messina 98166, Italy

<sup>c</sup> Dipartimento di Scienze Chimiche, Università di Catania, V. le A. Doria 6, 95125 Catania, Italy

<sup>d</sup> Institute of Polymers, Composites and Biomaterials CNR-IPCB, Via P. Gaifami 18, 95126 Catania, Italy

<sup>e</sup> Dipartimento di Ingegneria, Università di Messina, C. da Di Dio, (S. Agata) 98166 Messina, Italy

<sup>f</sup> Departament d'Enginyeria Química, Universitat Rovira i Virgili, Tarragona 43007, Spain

<sup>g</sup> C.I.R.C.S.B, Unity of Messina, Viale F. Stagno D'Alcontres, 31, 98166, Messina, Italy

## ABSTRACT

We report a hybrid nanoassembly based on gold colloids decorated with a new thiolated amphiphilic cyclodextrin complexing dopamine (AuNPs@SC16SH/DA). The novel amphiphilic  $\beta$ -cyclodextrin SC16SH, bearing on average one thiol group at the end of an oligoethylene glycol chain per CyD unit, was obtained in a multi-step synthesis and fully characterized by NMR spectroscopy and MALDI analysis. The AuNPs@SC16SH hybrid assembly was prepared by mixing AuNPs and SC16SH in aqueous solution and investigated by UV/Vis and TEM measurements. The AuNPs@SC16SH/DA supramolecular assembly, bearing both thiol-stabilized gold nanoparticles and the neurotransmitter dopamine, has been conceived as stimuli-responsive delivery system able to control the release of dopamine upon proper stimuli. Two redox functionalities (*i.e.* the Au-S bond and the redox behaviour of dopamine) have been exploited to detach SC16SH/DA complex from the AuNPs@SC16SH/DA progenitor platform, using

32 dithiothreitol (DTT), and to detect the complex by cyclic voltammetry (CV). Following, dopamine  
33 was finally released from the SC16SH/DA assembly upon treatment with Brij® S20 and the free  
34 dopamine was monitored by CV. Overall, our hybrid nanoassemblies turned out to be able to  
35 release dopamine, upon combined action of redox and digestion agents in medium emulating  
36 biological environment.

37 **Keywords:** amphiphilic cyclodextrins, nanovesicles, gold colloids, hybrid assemblies, dopamine,  
38 cyclic voltammetry

39

## 40 1. INTRODUCTION


41 The development of nanostructured plasmonic hybrid assemblies is a crucial step for the  
42 fabrication of technological devices with great potential in detection/diagnosis of various diseases  
43 and in delivery of bioactive compounds for therapeutic applications.<sup>1,2</sup> Colloidal nanoplasmonics  
44 exploit the interactions of membranes, proteins, or extracellular vesicles (EV) with gold  
45 nanoparticles based-assemblies for detection of peculiar biomarkers in biological environment.<sup>3</sup>  
46 In this direction, the design of novel nanovesicles with plasmonic outputs together with the  
47 knowledge of their mechanical properties, assumes utmost importance for understanding their  
48 biological behaviour including cell adhesion, uptake and release of cargo,<sup>4</sup> specially with regards  
49 to gold nanosystems that interface with neuronal biology.

50 In the treatment of neurological disorders, such as Parkinson's disease (PD), the restoration of  
51 adequate dopamine (DA) levels in dopaminergic cells is a great challenge.<sup>5</sup> Deficiency of DA in  
52 the brain of PD patients can be addressed by designing delivery nanosystems loading DA,  
53 permeable to the brain blood barrier (BBB)<sup>6</sup> and able to gradually release the neurotransmitter in  
54 neuronal cells.<sup>7</sup> Gold nanoparticles (AuNPs) are promising nanophototherapeutic and nanoprobe  
55 tools for penetrating BBB and interacting with central nervous system.<sup>8</sup> They are prone to both  
56 delivering DA<sup>9</sup> and monitoring DA release by intracellular AuNPs plasmonic band changes.<sup>10</sup>  
57 Cyclodextrins (CyDs) are nano-macrocyclic oligosaccharides able to complex various drugs,  
58 favouring their entrapment and delivery through modulation of host-guest interaction.<sup>11</sup>  
59 Amphiphilic CyDs (ACyDs) are an intriguing class of macromolecular glyco carriers able to form  
60 differently-shaped bio-soft nanostructures according to the hydrophobic/hydrophilic balance and

61 charge of moieties grafted on CyD rims.<sup>12-14</sup> Interestingly, ACyDs can form bilayer or multilayer  
62 vesicles as a result of self-assembly with lipids<sup>15</sup> or upon plasmids arrangement into the layers.<sup>16-</sup>  
63 <sup>18</sup> ACyDs bearing oligoethylene glycol chain on the secondary CyD side and thioalkyl groups on  
64 primary one were widely investigated in delivery of anticancer<sup>19</sup> and /or phototherapeutic guests<sup>20,</sup>  
65 <sup>21</sup>and as components of self- assembled- hybrids for biosensing<sup>22</sup> or stimuli-responsive  
66 hydrogels.<sup>23</sup> Nanovesicles of ACyD were recently proposed as cues to guide cell adhesion<sup>24</sup> or  
67 form stable emulsions for host/guest complexation.<sup>25</sup> Moreover various teams studied ACyDs  
68 decorating AuNPs for surface Raman scattering (SERS)<sup>26</sup> or for photothermal therapy (PTT)  
69 applications.<sup>27-29</sup> CyDs can form inclusion complexes with DA<sup>30,31</sup> and this feature was exploited  
70 to develop platforms for DA sensing.<sup>32-35</sup> Along this direction, AuNPs decorated with CyDs  
71 entrapping DA were proposed for colorimetric and electrochemical biosensing.<sup>36-38</sup> In the field of  
72 neurological nanodelivery, CyD nanosponges were designed to control the *in vitro* release of more  
73 stable dopamine derivative (i.e. L-DOPA).<sup>39</sup> In this research area, recently, some of us proved  
74 conceptually the release of DA and L-DOPA by electrical stimuli on a device built with cationic  
75 ACyDs supported on polycrystalline Au.<sup>40</sup> One of the main biochemical features of dopaminergic  
76 neurons is the alterations of thiol-dependent redox biochemical signals, involving decreased levels  
77 of glutathione (GSH) and reductase enzymes (i.e. methionine sulfoxide reductase A, MsrA) which  
78 are able to protect proteins from oxidative stress and avoid their further aggregation in neurotoxic  
79 oligomers.<sup>41</sup> To address the previous issues, therapeutic strategies for managing PD are aimed at  
80 enhancing functions of reductase enzymes<sup>42</sup> which on the other hand could help in DA refilling,  
81 upon redox-stimulated release of this neurotransmitter, in analogy with pH-responsive drug release  
82 from thiolated Au nanoplatfoms.<sup>43</sup> Moreover, the design of novel plasmonic nanovesicles  
83 bearing biorelevant groups (i.e. -SH groups)<sup>44</sup> and entrapping a neurotransmitter could play a key  
84 role in the interaction of plasmonic nanoparticles with neuronal cells. Nanostructured plasmonic  
85 hybrid assemblies can be fruitfully exploited to trigger a range of biological responses in neuronal  
86 tissues, including modulation of neuronal activity upon delivery of specific therapeutic agents,  
87 probes, or biological materials to targeted cells.<sup>45</sup>

88 To meet these needs, here we newly report AuNPs decorated with a novel thiolated amphiphilic  
89  $\beta$ -cyclodextrin (SC16SH) incorporating DA (AuNPs@SC16SH/DA, Scheme 1) able to release  
90 DA upon external stimuli in aqueous buffered medium. The thiolated amphiphilic CyD SC16SH  
91 was able to build up deeply interdigitated bi- and multilayers which covered AuNPs, forming

92 stable hybrid nanoassemblies in aqueous medium. Hence, upon DA complexation, the two redox  
93 functionalities (*i.e.* the Au-S bond and the redox behaviour of dopamine) were exploited to detach  
94 and detect, by cyclic voltammetry, SC16SH/DA complex from the AuNPs@SC16SH/DA  
95 progenitor platform, and to detect the free DA finally released from the SC16SH/DA assembly.



96

97 **Scheme 1.** Sketched view of AuNPs@SC16SH/DA nanoassemblies.

## 98 2. MATERIALS AND METHODS

99 **Materials.** All solvents and reagents were obtained from commercial sources and purified before  
100 use if necessary. Merck Kieselgel 60F254 plates were used for TLC, and Sephadex LH-20 for  
101 column chromatography. Hydrogen tetrachloroaurate (III) hydrate (99.9%) was supplied by Strem  
102 Chemicals.  $\beta$ -Cyclodextrin, citric acid and dopamine hydrochloride (DA, MW= 189.64 g/mol)  
103 were purchased by Sigma Aldrich. All the solutions for spectroscopic characterization were  
104 prepared in pure microfiltered water (Galenica Senese) or in phosphate buffer at pH 7.4 and  
105 analyzed at room temperature ( $r.t \cong 25^\circ\text{C}$ ).

106

107 **Synthesis.**

108 **General procedure for the synthesis of compounds 2-4.** Compounds 2-4 were synthesized as  
109 previously reported, by using the Gabelle&Defaye, Ling et al. and Mazzaglia et al. procedures for  
110 **2**,<sup>46</sup> **3**,<sup>47</sup> and **4**,<sup>48</sup> respectively.

111 **General procedure for the synthesis of compound 5 (SC16I).** Heptakis[6-deoxy-6-hexadecylthio-  
112 2-oligo(ethylene glycol)]- $\beta$ -cyclodextrin **4** (SC16OH) (0.5 g, 0.15 mmol) was dissolved in dry  
113 dimethylformamide (DMF) (15 mL) under inert atmosphere. Dry and recrystallized  
114 triphenylphosphine (Ph<sub>3</sub>P) (20 equiv) was added and heated at 100°C for 20 min. N-  
115 iododisuccinimide (NIS) (20 equiv) was then added. The mixture was stirred at 100 °C for 24 h  
116 under nitrogen atmosphere. The mixture was allowed to cool down to r.t. and precipitated in  
117 EtOH/H<sub>2</sub>O (1:1). The resulting solid was isolated by filtration and purified by size-exclusion  
118 chromatography (Sephadex LH-20) with CHCl<sub>3</sub>/CH<sub>3</sub>OH (1:1) as eluent, to give product **5**. Yield:  
119 30%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.88 (t, 21 H, CH<sub>3</sub>), 1.26 (br s, 182 H, CH<sub>2</sub>), 1.52-1.63 (m,  
120 14 H, CH<sub>2</sub>), 2.04 (br, OH), 2.51-2.65 (m, 14 H, SCH<sub>2</sub>), 2.78 (m, 2H, CH<sub>2</sub>I), 2.88-3.20 (m, 14 H,  
121 H<sub>6</sub>), 3.46-4.15 (m, ca. 82 H, H<sub>2</sub>-5 and OCH<sub>2</sub>CH<sub>2</sub>O), 5.04 (br, 7 H, H<sub>1</sub>). <sup>13</sup>C NMR (125 MHz,  
122 CDCl<sub>3</sub>):  $\delta$  = 3.00 (CH<sub>2</sub>I), 14.1 (CH<sub>3</sub>), 22.7 (CH<sub>2</sub>), 28.9 (CH<sub>2</sub>), 29.1 (CH<sub>2</sub>), 29.4 (CH<sub>2</sub>), 29.5 (CH<sub>2</sub>),  
123 29.7 [(CH<sub>2</sub>)<sub>n</sub>], 31.9 (CH<sub>2</sub>), 32.0 (CH<sub>2</sub>S), 33.7 (C<sub>6</sub>), 61.5 (CH<sub>2</sub>OH), 69.8-72.9 (C<sub>3</sub>, C<sub>5</sub>, CH<sub>2</sub>O),  
124 80.2-81.7 (C<sub>2</sub>, C<sub>4</sub>), 101.0 (C<sub>1</sub>). MALDI-TOF: M<sub>w</sub>=3390 Da; M<sub>n</sub>=3340 Da. At the most abundant  
125 peak, the average number of ethylene oxide units (n) resulted equal to 12.

126 **General procedure for the synthesis of compound 6 (SC16SH) and 7 (SC16S-mal).** Compound  
127 **5** (0.5 g, 0.14 mmol) was dissolved in dry DMF (15 mL) under nitrogen atmosphere. Thiourea (20  
128 equiv) was added and the reaction mixture was heated at 70°C for 24 h under nitrogen atmosphere.  
129 The DMF was removed under reduced pressure to give a yellow oil, which was dissolved in water  
130 (10 mL). A solution of sodium hydroxide (5 mL) was added and the mixture was gently heated at  
131 50°C under nitrogen atmosphere for 1 h. The suspension was acidified with 1 M HCl (4 mL) and  
132 stirred for 2 h. The resulted precipitated was collected by filtration and washed with H<sub>2</sub>O. The  
133 product **6** was dried in a vacuum oven. Yield: 95%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.88 (t, 21  
134 H, CH<sub>3</sub>), 1.25 (br s, 182 H, CH<sub>2</sub>), 1.45-1.67 (m, 14 H, CH<sub>2</sub>), 2.53-2.63 (m, 14 H, SCH<sub>2</sub>), 2.67 (m,  
135 2H, CH<sub>2</sub>SH), 2.90-3.07 (m, 14 H, H<sub>6</sub>), 3.35-4.10 (m, ca. 82 H, H<sub>2</sub>-5 and OCH<sub>2</sub>CH<sub>2</sub>O), 5.02 (br, 7  
136 H, H<sub>1</sub>). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.1 (CH<sub>3</sub>), 22.7 (CH<sub>2</sub>), 28.5 (CH<sub>2</sub>), 29.1 (CH<sub>2</sub>), 29.4  
137 (CH<sub>2</sub>), 29.5 (CH<sub>2</sub>), 29.7 (CH<sub>2</sub>), 29.8 [(CH<sub>2</sub>)<sub>n</sub>], 31.9 (CH<sub>2</sub>S), 33.7 (C<sub>6</sub>), 39.2 (CH<sub>2</sub>SH), 61.4  
138 (CH<sub>2</sub>OH), 69.9-73.3 (C<sub>3</sub>, C<sub>5</sub>, CH<sub>2</sub>O), 79.8-81.2 (C<sub>2</sub>, C<sub>4</sub>), 101.1 (C<sub>1</sub>). MALDI-TOF: M<sub>w</sub>=3240

139 Da; Mn=3170 Da. Main peaks (detected as  $MK^+$ ) at  $m/z$   $3055 + n \cdot 44$  (range  $n$  from 4 to 18,  $n$ =  
140 sum of ethylene glycol repetitive units in the oligomers chains; at the most abundant peak, the  
141 average number of ethylene oxide units ( $n$ ) resulted equal to 12).

142 A labelling reaction was performed by reacting **SC16SH (6)** with maleimide in water solution  
143 for 2 h at rt under nitrogen, leading to the thiosuccinimide **SC16S-mal (7)**. The dried sample,  
144 without purification, was analysed by MALDI-TOF:  $M_w$ =3340 Da;  $M_n$ =3270 Da. Main peaks  
145 (detected as  $MK^+$ ) at  $m/z$   $3152 + n \cdot 44$  (range  $n = 5-18$ ; at the most peak, the average number of  
146 ethylene oxide units ( $n$ ) resulted equal to 12).

147

### 148 **Preparation of the supramolecular hybrid assemblies**

149 **General remarks.** Gold nanoparticles (AuNPs) were prepared according to a slightly modified  
150 literature procedure through chemical reduction of gold precursor by citric acid.<sup>49</sup> Briefly, to a  
151 hydrogen tetrachloroaurate trihydrate ( $H AuCl_4 \cdot 3H_2O$ ) solution ( $[Au^{3+}] = [Au] = 0.15$  mM) at  
152 reflux, citric acid (7.8mM) was added under stirring till color change from pale yellow to purple,  
153 indicating the formation of the metallic nanoparticles. All SC16SH nanoassemblies ( $[SC16SH] =$   
154  $50$   $\mu M$ ) were prepared by hydration of organic film of SC16SH with ultrapure water in  $CH_2Cl_2$ ,  
155 ultrasonication (20 min) by microtip probe (power 35%) at  $4^\circ C$  (UW 2070 SONOPULS, Bandelin  
156 Electronic, Berlin, Germany) and equilibration at r.t.

157 **Preparation of SC16SH/DA nanoassemblies.** SC16SH/DA nanoassemblies were prepared at 1:1  
158 molar ratio ( $[SC16SH] = [DA] = 50$   $\mu M$ ). An amount of SC16SH stock solution in  $CH_2Cl_2$  (1  
159 mg/mL) was evaporated to obtain a film which was hydrated with DA aqueous solution (2 mL, 50  
160  $\mu M$ ). The dispersion was sonicated (20 min) by probe sonicator in an ice bath, equilibrated for 20  
161 min at r.t and utilized as prepared or by further dilution. As a comparison, SC16SH/DA assemblies  
162 at various concentration ( $[SC16SH] = [DA] = 1$  and  $10$   $\mu M$ ) were prepared. Host-guest  
163 competition experiments were carried out by addition of 1-adamantanemethylammonium chloride  
164 (100, 200  $\mu M$  and 1 mM) to SC16SH/DA ( $[SC16SH] = [DA] = 50$   $\mu M$ ) aqueous dispersion.

165 **Preparation of AuNPs@SC16SH and AuNPs@SC16SH/DA assemblies** AuNPs@SC16SH and  
166 AuNPs@SC16SH/DA hybrid assemblies were prepared in aqueous solution ( $V = 2$  mL) by mixing  
167 AuNPs ( $V = 1$  mL,  $[Au] = 0.15$  mM,) with an aqueous dispersion of SC16SH nanoassemblies or  
168 with preformed SC16SH@DA (*see above*) in order to have a final aqueous dispersion with  $[Au]$   
169  $= 75$   $\mu M$  ( $\cong 15$   $\mu g/mL$ ) and  $[SC16SH] = [DA] = 1$   $\mu M$  ( $SC16SH \cong 3.4$   $\mu g/mL$ ,  $DA \cong 0.19$   $\mu g/mL$ ).

170 All the assemblies were centrifuged with an Amicon® centrifugal filter (MW cut-off 3 kDa, 10  
171 min, 13800 x g) to remove eventual reactants or DA in excess and the material in the filter was  
172 resuspended in 0.1 M phosphate buffer for cyclic voltammetry (CV) measurements.

173 **DA release experiments.** A 5 µL aliquot of a 0.01 M stock solution of dithiothreitol (DTT) in  
174 water was added to 500 µL of freshly prepared AuNPs@SC16SH/DA ([DA]= 1 µM). After  
175 shacking for 30 min, the assemblies were filtered with an Amicon® centrifugal filter (MW cut-off  
176 3000, 10 min, 13800 x g) to remove DTT in excess. The filtrate was discarded and the material in  
177 the filter was diluted again to 500 µL with 0.1 M phosphate buffer pH 7.4. A portion of the sample  
178 (80 µL) was then analyzed by cyclic voltammetry. To 400 µL of the above dispersion, Brij® S20  
179 (4 µL) was added and the sample was gently shacked for 30 minutes. Immediately after mixing,  
180 80 µL of the sample were taken and filtered with an Amicon® centrifugal filter (MW cut-off 3  
181 kDa, 10 min, 13800 x g). The filtrate, containing released DA, was diluted back to 80 µL with 0.1  
182 M phosphate buffer pH 7.4, analyzed by cyclic voltammetry and discarded. This process was made  
183 after 5, 10, 20 and 30 minutes of mixing. Above 30 minutes, no significant increase in the DA  
184 redox signal was observed. The percentage of released DA (DA%) (mg of released DA/mg of  
185 initial amount of DA × 100) in the SC16SH/DA and AuNPs@SC16SH/DA nanoassemblies were  
186 estimated by dividing the current at 0.4 V in the filtrate after 20 minutes of Brij® S20 treatment  
187 with that of a 1 µM DA solution in 0.1 M phosphate buffer pH 7.4 after subtracting the baseline.

188

189 **NMR and MALDI-TOF characterization.** <sup>1</sup>H and <sup>13</sup>C-NMR spectra were obtained on a Varian  
190 Unity Inova 500MHz spectrometer at room temperature (r.t. ≅ 25°C). The chemical shifts (δ) are  
191 expressed in ppm. gHSQCAD experiments were performed using Varian standard pulse  
192 sequences. UV/Vis spectra were collected using a Hewlett- Packard mod. 8453 diode array  
193 spectrophotometer, using quartz cells with 1 cm path length (d). The MALDI-TOF mass spectra  
194 were recorded using a Perseptive Voyager DE instrument equipped with a nitrogen laser (emission  
195 at 337 nm for 3 ns) and a flash AD converter (500 MHz) (see SI for details).<sup>50, 51</sup>

196

197 **Transmission electron microscopy (TEM).** TEM analyses were carried out with a JEOL JEM  
198 2010 analytical electron microscope (LaB<sub>6</sub> electron gun) operating at 200 kV and equipped with a

199 Gatan 794 Multi-Scan CCD camera for digital imaging. TEM samples were prepared by dispersing  
200 the sample in isopropanol solution under ultrasonic agitation and placing a drop of the solution on  
201 400 mesh holey carbon coated copper grids. AuNPs, SC16SH and AuNPs@SC16SH  
202 nanoassemblies size distribution was obtained by acquiring TEM images at low magnification  
203 randomly throughout the sample and measuring the sizes of more than 500 particles from the  
204 corresponding TEM images.

205

206 **Electrochemistry.** Electrochemical measurements were performed on a PC controlled  
207 PGSTAT12 Autolab potentiostat (EcoChemie, The Netherlands) using carbon screen-printed  
208 electrodes (SPEs, from DropSens SL, Oviedo, Spain). These electrodes integrate a 4 mm carbon  
209 working electrode, a carbon counter electrode and an Ag/AgCl reference electrode in a ceramic  
210 support. Before use, the SPEs were pre-treated in sulfuric acid solution (1 M) with three potential  
211 cycles in the range 0-1.6 V at 50 mV/s scan rate, washed thoroughly with MilliQ water and dried  
212 with nitrogen. The solutions (~80  $\mu$ L) were placed over the SPEs positioned horizontally and  
213 analyzed by cyclic voltammetry in the potential range -0.2 V to +0.6 V vs. Ag/AgCl.

214

215


### 216 **3. RESULTS AND DISCUSSION**

#### 217 **3.1.Synthesis and characterization of novel thiolated amphiphilic cyclodextrin (SC16SH)**

218 The novel amphiphilic  $\beta$ -cyclodextrin SC16SH, bearing prevalently one thiol group at the end  
219 of an oligoethylene glycol chain per CyD unit, was obtained in a multi-step synthesis (Figure 1A)  
220 starting from the commercial  $\beta$ -cyclodextrin (**1**). As previously reported, a perbromination reaction  
221 at C<sub>6</sub> of **1** was carried out with N-bromosuccinimide and triphenylphosphine, leading to heptakis-  
222 (6-bromo-6-deoxy)- $\beta$ -cyclodextrin **2**.<sup>46</sup> Then, the thioether **3**<sup>48, 52</sup> was prepared by nucleophilic  
223 displacement reaction, in the presence of 1-hexadecanethiol and potassium tert-butoxide. The  
224 subsequent grafting of polyethylene glycol at the secondary rim was performed in tetra-N-  
225 methylurea, using ethylene carbonate and K<sub>2</sub>CO<sub>3</sub>, yielding the amphiphilic  $\beta$ -cyclodextrin **4**  
226 (SC16OH). The unprecedented iodination of oligoethylene glycol chains of SC16OH was carried  
227 out with N-iodosuccinimide and triphenylphosphine in anhydrous DMF at 100°C, to obtain

228 prevalently the mono iodinate compound **5** (SC16I). Nevertheless, considering the synthetic route,  
 229 the formation of less abundant multi iodinate species cannot be ruled out. After purification by  
 230 size-exclusion chromatography, SC16I reacted with thiourea to replace the terminal iodine on the  
 231 oligoethylene glycol chains with -SH groups, leading to the thiolated compound **6** (SC16SH)  
 232 (Figure 1A).

233 The new products were fully characterized by spectroscopic methods ( $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$ ,  
 234 HSQC experiments; Figures 1B and S1-S6) and MALDI-TOF MS analyses (Figure 2). After  
 235 iodination, a characteristic signal appears in  $^{13}\text{C}$  NMR spectrum at 3.00 ppm (Figure S2), as  
 236 expected for the  $-\text{CH}_2\text{I}$ . After reaction with thiourea, that signal disappears and a new one can be  
 237 detected at 39.2 ppm, attributed to the  $-\text{CH}_2\text{SH}$ , supporting the complete iodine to SH conversion.  
 238 Moreover, the iodination in cyclodextrin **5** and the presence of the  $-\text{SH}$  group in **6** were further  
 239 confirmed by HSQC experiments (Figures S3 and S6). Specifically, Figure 1B shows a  
 240 magnification of SC16SH HSQC spectrum highlighting the crosspeak between the resonance at  
 241 2.67 ppm in the  $^1\text{H}$  NMR spectrum (top projection) and the signal at 39.2 ppm in the  $^{13}\text{C}$  NMR  
 242 spectrum (left side projection), attributed to the  $-\text{CH}_2\text{SH}$  group. Nevertheless, considering the  
 243 synthetic procedure and the complexity of the spectrum, the presence of a mixture of mono- (the  
 244 most abundant) and multi-thiolated species could be considered.



245

246 **Figure 1.** A) Multi-step synthesis of amphiphilic cyclodextrins SC16I and SC16SH. a) Ph<sub>3</sub>P, NBS, dry  
247 DMF, 65°C; b) C<sub>16</sub>H<sub>33</sub>SH, t-BuOK, dry DMF, 80°C; c) K<sub>2</sub>CO<sub>3</sub>, ethylene carbonate, tetra-N-methyl urea,  
248 150°C; d) Ph<sub>3</sub>P, NIS, dry DMF, 100°C; e) thiourea, dry DMF, 70°C. B) Magnification of HSQC spectrum  
249 of SC16SH, showing –CH<sub>2</sub>SH crosspeak.


250  
251 The structure of the samples **4**, **5**, **6** was also confirmed by means of MALDI-TOF MS experiments  
252 (Figure 2). In particular, the mass spectrum of **4** showed a molecular mass distribution in the range  
253 2750-4000 Da, with the most abundant peak at about 3391 Da (M<sub>w</sub> = 3330 Da and M<sub>n</sub> = 3240  
254 Da, see SI for details) and consisted mainly of a series of peaks (Figure 2a) at m/z 3039 + n\*44  
255 (range n = 5-18; n = sum of ethylene glycol repetitive units in the oligomeric chains),  
256 corresponding to molecular ions of **4**, detected as [M]K<sup>+</sup>.

257 The mass spectrum of **5** showed molecular mass distribution in the range 2750-4000 Da, with the  
258 most abundant peak at about 3501 Da (M<sub>w</sub> = 3390 Da and M<sub>n</sub> = 3340 Da) (Figure 2b) and  
259 consisted mainly of a series of peaks at m/z 3149 + n\*44 (range n = 5-18; n = sum of ethylene  
260 glycol repetitive units in the oligomeric chains), corresponding to molecular ions of **5**, detected as  
261 [M]K<sup>+</sup>, having Iodine as end-group in one ethylene glycol oligomeric branch. Nevertheless,  
262 considering the synthetic route and the presence of a more complex peaks cluster, the formation  
263 of less abundant species bearing multi iodinate oligoethylene glycol chains cannot be excluded.

264 The mass spectrum of **6** showed a molecular mass distribution in the range 2750-4000 Da, with  
265 the most abundant peak at about 3407 Da (M<sub>w</sub> = 3240 Da and M<sub>n</sub> = 3170 Da) and consisted  
266 mainly of a series of peaks (Figure 2c) at m/z 3055 + n\*44 (range n = 5-18; n = sum of ethylene  
267 glycol repetitive units in the oligomeric chains), corresponding to molecular ions of **6**, detected as  
268 [M]K<sup>+</sup>, having -SH as end-group in one ethylene glycol oligomeric branch. Due to the presence of  
269 multi iodinated chains in compound **5**, the formation of multi thiolated species in **6** cannot be  
270 excluded.

271 To further confirm the presence of sulfhydryl-reactive chemical groups, a typical maleimide-thiol  
272 coupling reaction was performed *in-situ* by adding a water solution of maleimide to SC16SH  
273 (Scheme S1). The mixture was stirred for 2 h and the dried sample, without purification, was  
274 analysed by MALDI-TOF. The mass spectrum of the thiosuccinimide derivative **7** (SC16S-mal)  
275 showed a series of peaks (Figure 2d) at m/z 3152 + n\*44 (range n = 5-18), shifted forward, respect  
276 to SC16SH, by 97 amu (molecular weight of maleimide), corresponding to molecular ions of **7**

277 having the newly formed succinimide ring as end-group in ethylene glycol oligomer branch  
 278 (Scheme S1) and detected as  $[M]K^+$ . Moreover, for all the analysed compound, at the most  
 279 abundant oligomeric species, the average number of ethylene oxide units ( $n$ ) resulted equal to 12.




280  
 281 **Figure 2.** Positive MALDI-TOF mass spectra of: a) SC16OH (**4**); b) SC16I (**5**); c) SC16SH, (**6**);  
 282 d) SC16S-mal (**7**). For sake of clarity, only more abundant oligomeric species are labelled.

### 284 3.2. Supramolecular hybrid assemblies preparation and characterization

285 3.2.1. Hybrid Assemblies based on Thiolated  $\beta$ -Amphiphilic CyD decorated- Gold Colloids  
 286 ( $AuNPs@SC16SH$ )

287 Hybrid assemblies based on AuNPs@SC16SH were prepared by capping reaction of SC16SH ( $\cong$   
288 1  $\mu$ M) on AuNPs ( $[Au] = 75 \mu$ M) in aqueous solutions at Au/SC16SH w/w ratio of about 4.4 by  
289 slightly modifying the already reported capping reaction with cationic ACyD.<sup>29</sup> The UV/Vis  
290 spectrum of AuNPs showed the characteristic plasmon resonance band centred at 526 nm (Figure  
291 3, trace a). By capping AuNPs with SC16SH, the appearance of a broad band at around 640 nm,  
292 accompanied by a decrease of the 526 nm band, was observed (Figure 3, trace b). Both these  
293 features became more relevant over the time (within 24 h), even if no changes and no precipitation  
294 occurred after one week, indicating a good stability of the colloidal construct (Figure 3, trace c, d).  
295 Moreover, by replacement of citrate on AuNPs with hydrophobic thiolates, precipitation could  
296 occur.<sup>53</sup> Therefore, a precise dosage of the amount of thiolated CyD ( $\leq 1 \mu$ M) was required to get  
297 water dispersible and stable SC16SH-capped AuNPs.




298  
299 **Figure 3.** UV/Vis spectra of AuNPs (trace a), AuNPs@SC16SH at t=0 (trace b), t= 24 h (trace c)  
300 and t= 7 days (trace d). Experimental conditions:  $[SC16SH] = 1 \mu$ M,  $d = 1$  cm, r.t.


301  
302 TEM micrographs on SC16SH (Figure 4A) showed nanoassemblies of vesicular aspect in  
303 agreement with previous results,<sup>12, 26, 28, 40</sup> particle size distribution analyses showed an average  
304 diameter of about 70-80 nm (inset of Figure 4A). By inspecting nanoassemblies at higher  
305 magnification, a high tendency to form multilayer vesicles was observed (Figures 4B and 4C).  
306 This behaviour was ascribed to the interdigitated packing between thiohexadecyl chain on primary  
307 rim of opposite CyDs (see Scheme 1).<sup>54</sup> However, also interlayers interactions could take place

308 between external hydrophilic chains on CyD secondary rims by oligoethylene glycol  
309 entanglements and/ or disulfuric bridges formation by -SH ends groups coupling.

310  
311 TEM of starting AuNPs dispersion typically showed NPs of 20-30 nm (Figure S7).  
312 AuNPs@SC16SH hybrid assemblies (Figure 5) revealed a slight clustering of the AuNPs covered  
313 by two or even more layers of thiolated amphiphilic cyclodextrin (Figures 5 B-E). Plausibly, deep  
314 interdigitated SC16SH bi- (about 2.7 nm thick film) or four-layers (about 5.0 nm) were present on  
315 the metallic surface due to the high affinity of thiol functionality towards AuNPs.<sup>43, 53</sup> Overall, it  
316 was possible to distinguish the single AuNPs@SC16SH nanoassembly with an average diameter  
317 of about 20-30 nm (inset of Figure 5A) and their bunches clusters of 150-300 nm



318  
319 **Figure 4.** Representative TEM micrographs of SC16SH vesicles (A, low magnification) with particle size  
320 distribution (inset of A) and focus on SC16SH vesicles multilayers (B and C, high magnification).  
321



322

323 **Figure 5.** Representative TEM images of AuNPs@SC16SH (A, low magnification) with particle size  
 324 distribution (inset of A). B-E: focus at high magnification on SC16SH bi- and multilayer covering AuNPs  
 325 (C and E are further magnified images of B and D, respectively).

326


327 *3.1.2. Supramolecular complexes with dopamine (AuNPs@SC16SH/DA), controlled release and*  
 328 *detection by electrochemistry*

329 SC16SH/DA and AuNPs decorated with thiolated ACyD/dopamine assemblies  
 330 (AuNPs@SC16SH/DA) were prepared in aqueous solution.

331 The complexation of dopamine was studied by electrochemistry. Figure 6a reports the cyclic  
 332 voltammograms (CV) of DA in phosphate buffer solution (pH 7.4) at different concentrations  
 333 before and after its interaction with SC16SH. At 50  $\mu\text{M}$  of DA, a quasi-reversible response is  
 334 observed, centered at 0.29 V vs. Ag/AgCl with a peak-to-peak separation of 190 mV corresponding  
 335 to the oxidation and reduction processes of DA. Upon interaction with SC16SH, the peaks  
 336 decreased in intensity and the peak-to-peak separation increased to 255 mV. This was consistent  
 337 with the entrapment of DA in SC16SH that reduced the diffusion coefficient due to its high  
 338 molecular weight, decreasing the current and partially hindering the electron transfer process of  
 339 DA, resulting in an increase of the peak-to-peak separation. The effect is observed over a large

340 concentration range (1 – 50  $\mu\text{M}$ ). In the presence of increasing concentrations of 1-  
341 adamantanemethylammonium chloride (up to 200  $\mu\text{M}$ ), the DA signal is partly restored (Figure  
342 6b) indicating the competition of the adamantane moiety for the cyclodextrin cavities resulting in  
343 a displacement of DA. However, by considering the partial displacement of DA by adamantane  
344 derivative, a strong interaction of DA with SC16SH can be supposed.

345




346

347 **Figure 6.** a) Cyclic voltammograms of DA (solid lines) and SC16SH/DA (dotted lines) at different  
348 concentrations of DA. b) Cyclic voltammograms of 50  $\mu\text{M}$  DA (trace i), SC16SH/DA (trace ii), and after  
349 addition of 1-adamantanemethylammonium chloride (100  $\mu\text{M}$ , trace iii and 200  $\mu\text{M}$ , trace iv). Experimental  
350 conditions: Supporting electrolyte: 0.1 M phosphate buffer pH 7.4. Scan rate: 100 mV/s.

351

352 The interaction of AuNPs with SC16SH/DA to form AuNPs@SC16SH/DA was confirmed by a  
353 further decrease in signal intensity of the CV of DA and an increase of peak-to-peak separation up  
354 to 262 mV (Figure 7a).  
355




356  
357 **Figure 7.** a) Cyclic voltammograms of DA (1  $\mu\text{M}$ ) before (trace i) and after interaction with SC16SH  
358 (SC16SH/DA, trace ii) and AuNPs (AuNPs@SC16SH/DA, trace iii). b) Cyclic voltammograms of  
359 AuNPs@SC16SH/DA before (trace i), after addition of DTT (0.1 mM) (trace ii), and after treatment with  
360 Brij® S20 (1%) for 30 minutes (trace iii). The inset shows the peak current at 0.4 V as function of time.  
361 Experimental conditions: SC16SH/DA and AuNPs@SC16SH/DA were both prepared at  $[\text{SC16SH}] = [\text{DA}]$   
362 = 1  $\mu\text{M}$ . Supporting electrolyte: 0.1 M phosphate buffer pH 7.4. Scan rate: 100 mV/s.

363  
364 Dithiothreitol (DTT) is widely used for displacing ligands from their gold nanoparticle conjugates,  
365 a crucial action for differentiating bound functional moieties.<sup>55</sup> DTT is a small molecule and should  
366 penetrate the corona assembly on AuNPs, linking to the Au surface by its two highly affine thiol

367 groups displacing other ligands from surface binding sites. Addition of DTT to  
368 AuNPs@SC16SH/DA provoked a slight increase of the peak current accompanied by a significant  
369 improvement of the reversibility of the DA redox process (Figure 7b, trace *ii*). This was tentatively  
370 ascribed to the competition of DTT for the Au-S sites in AuNPs@SC16SH/DA causing the  
371 detaching of SC16SH/DA complex, a process that could mimic, in principle, reductase enzymes  
372 in biological sites.<sup>56, 57</sup> To finally release DA from SC16SH/DA assembly, the non-ionic surfactant  
373 Brij® S20 was used to emulate the action of lipids on cell membranes for modulating drug  
374 permeability.<sup>58, 59</sup>

375 Five identical portions of the SC16SH/DA system were treated with the surfactant and filtered  
376 using a 3 kDa centrifugal filter right after treatment and after given periods of time. CV analysis  
377 of the filtrate immediately after addition showed a lack of DA signals, confirming the entrapment  
378 of DA in the SC16SH assembly (Figure S8). As time evolved, the peak current increased steadily  
379 to remain essentially constant after 20 min (Figure 7b, trace *iii*), pointing out the DA release over  
380 the time (inset of Fig. 7b). The percentage of released DA (DA %), estimated from the ratio  
381 between the anodic current at 0.4 V after treatment with Brij® with respect to a 1 μM DA stock,  
382 were 67, 71 and 78% in three separate experiments, with an average value of 72% of released DA.  
383 Scheme 2 shows a sketched view of the supposed dopamine release stimulated by DTT and  
384 digestion agent.



386 **Scheme 2:** Sketched view of dopamine release upon redox (DDT) and digestion agent (Brij S20)  
387 external stimuli.

388 Our strategy, which entails the self-assembly of hybrid nanovesicles and neurotransmitters,  
389 could be further explored to investigate their clustering with biological membranes or extracellular  
390 vesicles in order to elucidate physico-chemical parameters (i.e. nanomechanical features)<sup>4</sup> in cell  
391 uptake and drug release mechanisms. Further *in vitro* studies on real samples taking into account  
392 the influence of proteins and ionic strength on the release mechanism are currently underway.

393

#### 394 **4. CONCLUSIONS**

395 In conclusion, we proposed a nanoconstruct based on gold colloids decorated with a new thiolated  
396 amphiphilic cyclodextrin complexing dopamine prepared by a green capping reaction in aqueous  
397 solution. The AuNPs@SC16SH hybrid system forms nanoassemblies of about 20-30 nm and  
398 larger aggregates in which bi- or multilayer of amphiphilic cyclodextrin cover AuNPs. The hybrid  
399 system strongly entraps DA in aqueous medium, as proved through electrochemical detection by  
400 the reduction of diffusion coefficient due to its high molecular weight *vs* free DA. This property  
401 decreases the current, partially hindering the electron transfer process of DA, resulting in an  
402 increase of the peak-to-peak separation. Finally, our hybrid nanoassemblies based on  
403 AuNPs@SC16SH/DA served as stimuli-responsive delivery system able to release the  
404 neurotransmitter in biologically relevant medium upon combined action of agents (*i.e.* DTT and  
405 surfactants) leading to release about 70 % of free DA in 30 min. In perspective our findings could  
406 lay the groundwork to further investigate redox-responsive thiol-dependent drug delivery systems  
407 targeting dopaminergic neurons for the controlled release of dopamine, contributing to the design  
408 of novel therapeutic approaches for treating Parkinson's disease. Moreover, our plasmonic  
409 nanovesicles can be further investigated to elucidate their interaction with biological membranes  
410 and extracellular vesicles. Studies in *in vitro* models following this direction are in due course in  
411 our laboratories.

#### 412 **ACKNOWLEDGEMENTS**

413 This work was supported by EU projects ESF- EUROCORES (10-EuroBioSAS-FP-009)  
414 ‘Intelligent Cell Surfaces (ICS) and MIUR (PRIN 2010- 2011 Project No. 2010C4R8M8\_003),  
415 and PON03PE\_00216\_1 Drug Delivery.

416

417 **Supporting Information.** *MALDI-TOF characterization. Figures:* <sup>1</sup>H NMR of SC16I (Figure  
418 S1); <sup>13</sup>C NMR of SC16I (Figure S2); 2D HSQC of SC16I (Figure S3); <sup>1</sup>H NMR of SC16SH (Figure  
419 S4); <sup>13</sup>C NMR of SC16SH (Figure S5); 2D HSQC of SC16SH (Figure S6); “Click” synthesis of  
420 SC16S-mal for MALDI-TOF analysis (Scheme S1); TEM micrographs of AuNPs (Figure S7);  
421 Cyclic voltammograms after treatment of SC16SH/DA (Figure S8).

## 422 **Corresponding Author**

423 \*Antonino Mazzaglia, CNR-ISMN, Istituto per lo Studio dei Materiali Nanostrutturati, c/o  
424 Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, University of  
425 Messina, V. le F. Stagno D’Alcontres 31 98166, Messina, Italy.

426 Email: antonino.mazzaglia@cnr.it

## 427 **Author Contributions**

428 The manuscript was written through contributions of all authors. All authors have given approval  
429 to the final version of the manuscript. †M.T. and A.S. contributed equally.

430

431

## 432 **REFERENCES**

- 433 1. Grzelczak, M.; Liz-Marzán, L. M. Colloidal nanoplasmonics: from building blocks to  
434 sensing devices. *Langmuir*, **2013**, 29, (15), 4652- 4663.
- 435 2. Sancho-Albero, M.; Rubio Ruiz, B.; Pérez-López, A. M.; Sebastián, V.; Martin-Duque, P.;  
436 Arruebo, M.; J. Santamaría; Unciti- Broceta, A. Cancer-derived exosomes loaded with  
437 ultrathin palladium nanosheets for targeted bioorthogonal catalysis. *Nature Catalysis*,  
438 **2019**, 2, 864- 872.

- 439 3. Maiolo, D.; Paolini, L.; Di Noto, G.; Zendrini, A.; Berti, D.; Bergese, P.; Ricotta, D.  
440 Colorimetric nanoplasmonic assay to determine purity and titrate extracellular vesicles.  
441 *Anal. Chem.*, **2015**, 87, (8), 4168–4176.
- 442 4. Caselli, L.; Ridolfi, A.; Cardellini, J.; Sharpnack, L.; Paolini, L.; Brucale, M.; Valle, F.;  
443 Montis, C.; Bergese, P.; Berti, D. A plasmon-based nanoruler to probe the mechanical  
444 properties of synthetic and biogenic nanosized lipid vesicles. *Nanoscale Horiz.*, **2021**,  
445 Advance Article.
- 446 5. Charvin, D.; Medori, R.; Hauser R. A.; Rascol, O. Therapeutic strategies for Parkinson  
447 disease: beyond dopaminergic drugs. *Nat. Rev. Drug Discov.*, **2018**, 17, (11), 804–822.
- 448 6. Saraiva, C.; Praça, C.; Ferreira, R.; Santos, T.; Ferreira L.; Bernardino, L. Nanoparticle-  
449 mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative  
450 diseases. *J. Control. Rel.*, **2016**, 235, 34–47.
- 451 7. Pahuja, R.; Seth, K.; Shukla, A.; Shukla, R. K.; Bhatnagar, P.; Chauhan, L. K. S.; Saxena,  
452 P. N.; Arun, J.; Chaudhari, B. P.; Patel, D. K.; Singh, S. P.; Shukla, R.; Khanna, V. K.;  
453 Kumar, P.; Chaturvedi, R. K.; Gupta, K. C. Trans-Blood Brain Barrier Delivery of  
454 Dopamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Rats. *ACS*  
455 *Nano*, **2015**, 9, (5), 4850-4871.
- 456 8. Athira S.S.; Prajitha N., Mohanan P.V. Interaction of nanoparticles with central nervous  
457 system and its consequences. *Am. J. Med. Sci*, **2018**, 4, (1), 12–32.
- 458 9. Rout, J.; Swain, B. C.; Mishra P. P.; Tripathy, U. Spectroscopic insight into the interaction  
459 of dopamine with spherical gold nanoparticles. *J. Photoch. Photobio. B Biol.*, **2020**, 203,  
460 111770.
- 461 10. Qin, W. W.; Wang, S. P.; Li, J.; Peng, T. H.; Xu, Y.; Wang, K.; Shi, J. Y.; Fan C. H.; Li,  
462 D. Visualizing dopamine released from living cells using a nanoplasmonic probe.  
463 *Nanoscale*, **2015**, 7, 15070–15074.
- 464 11. Wankar, J.; Kotla, G. N.; Gera, S.; Rasala, S.; Pandit, A.; Rochev, A. Y. Recent advances  
465 in host–guest self- assembled cyclodextrin carriers: implications for responsive drug  
466 delivery and biomedical engineering. *Adv. Funct. Mater.*, **2020**, 30, 1909049.
- 467 12. Zagami, R.; Romeo A.; Mazzaglia, A. Bio-soft cyclodextrin nanomaterials. *Riv. Nuovo*  
468 *Cimento*, **2019**, 42, 407–441.

- 469 13. Rivero- Barbarroja, G.; Benito, J. M.; Ortiz Mellet, C.; García Fernández, J. M.  
470 Cyclodextrin-based functional glyconanomaterials. *Nanomaterials*, **2020**, 10, (12), 2517.
- 471 14. Varan, G.; Benito, J. M.; Ortiz Mellet, C.; Bilensoy, E. Development of polycationic  
472 amphiphilic cyclodextrin nanoparticles for anticancer drug delivery. *Beilstein J.*  
473 *Nanotechnol.*, **2017**, 8, 1457–1468
- 474 15. Zerkoune, L.; Lesieur, S.; Putaux, J. L.; Choisnard, L.; Gèze, A.; Wouessidjewe, D.;  
475 Angelov, B.; Vebert-Nardin, C.; Douch, J.; Angelova, A. Mesoporous self-assembled  
476 nanoparticles of biotransesterified cyclodextrins and nonlamellar lipids as carriers of  
477 water-insoluble substances. *Soft Matter*, **2016**, 12, 7539-7550.
- 478 16. Villari, V.; Mazzaglia, A.; Darcy, R.; O’Driscoll, C. M.; Micali, N. Nanostructures of  
479 cationic amphiphilic cyclodextrin complexes with DNA. *Biomacromolecules*, **2013**, 14,  
480 (3), 811–817.
- 481 17. Diaz Moscoso, A.; Guilloteau, N.; Bienvenu, C.; Méndez-Ardoy, A.; Jiménez Blanco, J.  
482 L.; Benito, J. M.; Le Gourriérec, L.; Di Giorgio, C.; Vierling, P.; Defaye, J.; Mellet, C. O.;  
483 García Fernández, J. M. Mannosyl-coated nanocomplexes from amphiphilic cyclodextrins  
484 and pDNA for site-specific gene delivery. *Biomaterials*, **2011**, 32, (29), 7263–7273.
- 485 18. Neva, T.; Carbajo- Gordillo, A. I.; Benito, J. M.; Lana, H.; Marcelo, G.; Ortiz Mellet, C.;  
486 Tros de Ilarduya, C.; Mendicuti, F.; García Fernández, J. M. Tuning the topological  
487 landscape of DNA–cyclodextrin nanocomplexes by molecular design. *Chem. Eur. J.*, **2020**,  
488 26, 15259 – 15269.
- 489 19. Bondi, M. L.; Scala, A.; Sortino, G.; Amore, E.; Botto, C.; Azzolina, A.; Balasus, D.;  
490 Cervello, M.; Mazzaglia, A. Nanoassemblies based on supramolecular complexes of  
491 nonionic amphiphilic cyclodextrin and Sorafenib as effective weapons to kill Human HCC  
492 cells. *Biomacromolecules*, **2015**, 16, (12), 3784–3791.
- 493 20. Conte, C.; Scala, A.; Siracusano, Sortino, G.; Pennisi, R.; G.; Piperno, A.; Miro, A.;  
494 Ungaro, F.; Sciortino, M. T.; Quaglia, F.; Mazzaglia, A. Nanoassemblies based on non-  
495 ionic amphiphilic cyclodextrin hosting Zn(II)-phthalocyanine and docetaxel: Design,  
496 physicochemical properties and intracellular effects. *Colloids Surfaces B: Biointerfaces*,  
497 **2016**, 146, 590–597.

- 498 21. Zagami, R.; Rapozzi, V.; Piperno, A.; Scala, A.; Triolo, C.; Trapani, M.; Xodo, L. E.;  
499 Monsù Scolaro, L.; Mazzaglia, A. Folate-Decorated Amphiphilic Cyclodextrins as Cell-  
500 Targeted Nanophototherapeutics. *Biomacromolecules*, **2019**, 20, (7), 2530–2544.
- 501 22. Muñoz, J.; Crivillers, N.; Ravoo, B. J.; Mas-Torrent, M. Cyclodextrin-based  
502 superparamagnetic host vesicles as ultrasensitive nanobiocarriers for electrosensing.  
503 *Nanoscale*, **2020**, 12, 9884-9889.
- 504 23. Chu, C.-W.; Ravoo, B. J. Hierarchical supramolecular hydrogels: self-assembly by  
505 peptides and photo-controlled release via host–guest interaction. *Chem. Commun.*, **2017**,  
506 53, 12450-12453.
- 507 24. Valle, F.; Tortorella, S.; Scala, A.; Cordaro, A.; Barbalinardo, M.; Biscarini, F.; Mazzaglia,  
508 A. Amphiphilic cationic cyclodextrin nanovesicles: a versatile cue for guiding cell  
509 adhesion. *Nanoscale Adv.*, **2020**, 2, 5897–5904.
- 510 25. Schluter, F.; Bela, M. M.; Glikman, D.; Braunschweig B.; Ravoo, B. J. A cyclodextrin  
511 surfactant for stable emulsions with an accessible cavity for host–guest complexation.  
512 *Chem. Commun.*, **2020**, 56, 15434-15437.
- 513 26. De Vries, W. C.; Niehues, M.; Wissing, M.; Würthwein, T.; Mäsing, F.; Fallnich, C.;  
514 Studer A.; Ravoo, B. J. Photochemical preparation of gold nanoparticle decorated  
515 cyclodextrin vesicles with tailored plasmonic properties. *Nanoscale*, **2019**, 11, 9384–9391.
- 516 27. Mazzaglia, A.; Trapani, M.; Villari, V.; Micali, N.; Marino Merlo, F.; Zaccaria, D.;  
517 Sciortino, M. T.; Previti, F.; Patanè S.; Monsu` Scolaro, L. Amphiphilic Cyclodextrins as  
518 Capping Agents for Gold Colloids: A Spectroscopic Investigation with Perspectives in  
519 Photothermal Therapy. *J. Phys. Chem. C*, **2008**, 112, 6764-6769.
- 520 28. Mazzaglia, A.; Monsù Scolaro, L.; Mezzi, A.; Kaciulis, S.; De Caro, T.; Ingo G. M.;  
521 Padeletti, G. Supramolecular Colloidal Systems of Gold Nanoparticles/Amphiphilic  
522 Cyclodextrin: a FE-SEM and XPS Investigation of Nanostructures Assembled onto Solid  
523 Surface. *J. Phys. Chem. C*, **2009**, 113, 12772–12777.
- 524 29. Trapani, M.; Romeo, A.; Parisi, T.; Sciortino, M. T.; Patanè, S.; Villari V.; Mazzaglia, A.  
525 Supramolecular hybrid assemblies based on gold nanoparticles, amphiphilic cyclodextrin  
526 and porphyrins with combined phototherapeutic action. *RSC Adv.*, **2013**, 3, 5607–5614.

- 527 30. Roy, N.; Saha, S.; Kundu, M.; Saha B. C.; Barman, S. Exploration of inclusion complexes  
528 of neurotransmitters with  $\beta$ -cyclodextrin by physicochemical techniques. *Chem. Phys.*  
529 *Lett.*, **2016**, 655–656, 43–50.
- 530 31. Prabhu, A. A. M.; Fatiha, M.; Leila, N.; Raj, T. A.; Navarro-González, I.; Periago, M. J.;  
531 Yáñez-Gascón; M. J.; Pérez-Sánchez, H. Investigation of 3D Contour Map and  
532 Intermolecular Interaction of Dopamine with  $\beta$ -Cyclodextrin and 2-Hydroxypropyl- $\beta$ -  
533 cyclodextrin. *J. Solution Chem.*, **2018**, 47, 409–429.
- 534 32. Zhang, Y.; Yuan, R.; Chai, Y.; Li, W.; Zhong X.; Zhong, H. Simultaneous voltammetric  
535 determination for DA, AA and  $\text{NO}_2^-$  based on graphene/poly-cyclodextrin/MWCNTs  
536 nanocomposite platform. *Biosens. Bioelectron.*, **2011**, 26, 3977–3980.
- 537 33. Abbaspour A.; Noori, A. A cyclodextrin host–guest recognition approach to an  
538 electrochemical sensor for simultaneous quantification of serotonin and dopamine.  
539 *Biosens. Bioelectron.*, **2011**, 26, 4674–4680.
- 540 34. Lee, C.-Y.; Hsua, D.-Y.; Prasanna, A.; Kalaivanic, R.; Hong, P.-D. Facile synthesis of  
541 hexagonal-shaped polypyrrole self-assembled particles for the electrochemical detection  
542 of dopamine. *Appl. Surf. Sci.*, **2016**, 363, 451–458.
- 543 35. Li, Z.; Van Guyse, J. F. R.; de la Rosa, V. R.; Van Gorp, H.; Walke, P.; Rodríguez  
544 González, M. C.; Uji-i, H.; Hoogenboom, R.; De Feyter S.; Mertens, S. F. L. One- Step  
545 Covalent Immobilization of  $\beta$ - Cyclodextrin on  $\text{sp}^2$  Carbon Surfaces for Selective Trace  
546 Amount Probing of Guests. *Adv. Funct. Mater.*, **2019**, 29, 1901488.
- 547 36. Wen, D.; Liu, W.; Herrmann, A.-K.; Haubold, D.; Holzschuh, M.; Simon F.; Eychmüller,  
548 A. Simple and Sensitive Colorimetric Detection of Dopamine Based on Assembly of  
549 Cyclodextrin- Modified Au Nanoparticles. *Small*, **2016**, 12, (18), 2439–2442.
- 550 37. Halawa, M. I.; Wua, F.; Fereja, T. H.; Loua B.; Xua, G. One-pot green synthesis of  
551 supramolecular  $\beta$ -cyclodextrin functionalized gold nanoclusters and their application for  
552 highly selective and sensitive fluorescent detection of dopamine. *Sensors and Actuators B*,  
553 **2018**, 254, 1017–1024.
- 554 38. Chang, Z.; Zhou, Y.; Hao, L.; Hao, Y.; Zhu X.; Xu, M. Simultaneous determination of  
555 dopamine and ascorbic acid using  $\beta$ -cyclodextrin/Au nanoparticles/graphene-modified  
556 electrodes *Anal. Methods*, **2017**, 9, 664-671.

- 557 39. Trotta, F.; Caldera, F.; Cavalli, R.; Soster, M.; Riedo, C.; Biasizzo, M.; Uccello Barretta  
558 G.; Balzano, F.; Brunella, V. Molecularly imprinted cyclodextrin nanosponges for the  
559 controlled delivery of L-DOPA: perspectives for the treatment of Parkinson's disease.  
560 *Expert Opin. Drug Del.*, **2016**, 13, 1671-1680.
- 561 40. Foschi, G.; Leonardi, F.; Scala, A.; Biscarini, F.; Kovtun, A.; Liscio, A.; Mazzaglia A.;  
562 Casalini, S. Electrical release of dopamine and levodopa mediated by amphiphilic  $\beta$ -  
563 cyclodextrins immobilized on polycrystalline gold. *Nanoscale*, **2015**, 7, 20025-20032.
- 564 41. Garcia-Garcia, A.; Zavala-Flores, L.; Rodriguez-Rocha H.; Franco, R.. Thiol-Redox  
565 Signaling, Dopaminergic Cell Death, and Parkinson's Disease. *Antiox. Redox Sign.*, **2012**,  
566 17, (12), 1765-1784.
- 567 42. Liu, F.; Hindupur, J.; Nguyen, J. L.; Ruf, K. J.; Zhu, J.; Schieler, J. L.; Bonham, C. C.;  
568 Wood, K. V.; Davisson, V. J.; Rochet, J.-C. Methionine sulfoxide reductase A protects  
569 dopaminergic cells from Parkinson's disease-related insults. *Free Radical Bio. Med.*, **2008**,  
570 45, (3), 242–255.
- 571 43. Ghorbani M.; Hamishehkar, H. Decoration of gold nanoparticles with thiolated pH-  
572 responsive polymeric (PEG-b-p(2-dimethylamio ethyl methacrylate-co-itaconic acid)  
573 shell: A novel platform for targeting of anticancer agent. *Mat. Sci. Eng. C-Mater.*, **2017**,  
574 81, (1), 561-570.
- 575 44. Idiago-López, J.; Moreno-Antolín, E.; de la Fuente, J. M.; Fratila, R. M. Nanoparticles and  
576 bioorthogonal chemistry joining forces for improved biomedical applications. *Nanoscale*  
577 *Adv.*, **2021**, (3), 1261-1292.
- 578 45. Paviolo, C.; Stoddart, P. R. Gold Nanoparticles for Modulating Neuronal Behavior.  
579 *Nanomaterials*, **2017**, 7(4), 92.
- 580 46. Gadelle A.; Defaye, J. Selective Halogenation at Primary Positions of  
581 Cyclomaltooligosaccharides and a Synthesis of Per- 3,6- anhydro  
582 Cyclomaltooligosaccharides. *Angew Chem Int Ed Engl*, **1991**, 30, (1), 78-80.
- 583 47. Ling, C.-C.; Darcy R.; Risse, W. Cyclodextrin liquid crystals: synthesis and self-  
584 organisation of amphiphilic thio- $\beta$ -cyclodextrins. *J. Chem. Soc., Chem. Commun.*, **1993**,  
585 438-440.
- 586 48. Mazzaglia, A.; Donohue, R.; Ravoo B. J.; Darcy, R. Novel Amphiphilic Cyclodextrins:  
587 Graft- Synthesis of Heptakis(6- alkylthio- 6- deoxy)-  $\beta$ - cyclodextrin 2-

- 588           Oligo(ethylene glycol) Conjugates and Their  $\omega$ - Halo Derivatives. *Eur. J. Org. Chem.*,  
589           **2001**, 9, 1715-1721.
- 590   49. Zhou H. S.; Aoki S.; Honma I.; Hirasawa, M.; Nagamune, T.; Komiyama, H.  
591           Conformational change of protein cytochrome b-562 adsorbed on colloidal gold particles;  
592           absorption band shift. *Chem. Commun.*, **1997**, 605-606.
- 593   50. Mineo, P.; Scamporrino E.; Vitalini, D. Effect of combined changes in delayed extraction  
594           time and potential gradient on the mass resolution and ion discrimination in the analysis of  
595           polydisperse polymers and polymer blends by delayed extraction matrix- assisted laser  
596           desorption/ionization time- of- flight mass spectrometry. *Rapid Commun. Mass*  
597           *Spectrom.*, **1999**, 13, 2511–2517.
- 598   51. Mineo, P.; Scamporrino, E.; Vitalini, D.; Alicata R.; Bazzano, S. Effect of delay time and  
599           grid voltage changes on the average molecular mass of polydisperse polymers and  
600           polymeric blends determined by DE MALDI-TOF. *Rapid Commun. Mass Spectrom.*,  
601           **2005**, 19, 2773–2779.
- 602   52. Ravoo B. J.; Darcy, R. Cyclodextrin Bilayer Vesicles. *Angew. Chem. Int. Ed.*, **2000**, 39,  
603           (23), 4324-4326.
- 604   53. Liu, J.; Xu R.; Kaifer A. E. In situ modification of the surface of gold colloidal particles.  
605           preparation of cyclodextrin-based rotaxanes supported on gold nanospheres. *Langmuir*,  
606           **1998**, 14, (26), 7337-7339.
- 607   54. Falvey, P.; Lim, C. W.; Darcy, R.; Revermann, T.; Karst, U.; Giesbers, M.; Marcelis, A.  
608           T. M.; Lazar, A.; Coleman, A. W.; Reinhoudt, D. N.; Ravoo, B. J. Bilayer vesicles of  
609           amphiphilic cyclodextrins: host membranes that recognize guest molecules. *Chem. Eur. J.*,  
610           **2005**, 11, 1171 – 1180.
- 611   55. Tsai, D.-H.; Shelton, M. P.; Del Rio, F. W.; Elzey, S.; Guha, S.; Zachariah, M. R.; Hackley,  
612           V. A. Quantifying dithiothreitol displacement of functional ligands from gold  
613           nanoparticles. *Anal. Bioanal. Chem.*, **2012**, 404, (10), 3015–3023.
- 614   56. Mazzaglia, A.; Valerio, A.; Micali, N.; Villari, V.; Quaglia, F.; Castriciano, M. A.; Monsù  
615           Scolaro, L.; Giuffrè, M.; Siracusano G.; Sciortino, M. T. Effective cell uptake of  
616           nanoassemblies of a fluorescent amphiphilic cyclodextrin and an anionic porphyrin. *Chem.*  
617           *Commun.*, **2011**, 47, 9140–9142.

- 618 57. Yang, W.; Yu, C.; Wu, C.; Yao, S. Q.; Wu, S. Cell-penetrating poly(disulfide)-based star  
619 polymers for simultaneous intracellular delivery of miRNAs and small molecule drugs.  
620 *Polym. Chem.*, **2017**, 8, 4043-4051.
- 621 58. Yu, H.; Hu, Y. Q.; Ip, F. C. F.; Zuo, Z.; Yi, F. Ha.; Ip N. Y. Intestinal transport of bis(12)-  
622 hupyrindone in Caco- 2 cells and its improved permeability by the surfactant Brij- 35.  
623 *Biopharm Drug Dispos.*, **2011**, 32, (3):140–150.
- 624 59. Xiong, W.; Sang, W.; Linghu, K. G.; Zhong, Z. F.; Cheang, W. S.; Li, J.; Hu, Y. J.; Yu,  
625 H.; Wang Y. T. Dual-functional Brij-S20-modified nanocrystal formulation enhances the  
626 intestinal transport and oral bioavailability of berberine. *Int. J. Nanomedicine*, **2018**, 13,  
627 3781–3793.
- 628